Last edition
News about "NMPA-Backed Combination Trial Approval"
Mabwell Advances ADC Manufacturing Pipeline With NMPA-Backed Combination Trial Approval
Mabwell, an innovation-driven biopharmaceutical company with fully integrated capabilities spanning research and development, manufacturing, and commercialisation, announced that China’s National Medical Products Administration (NMPA) has approved the initiation of clinical trials for its independently developed B7-H3–targeting antibody–drug conjugate.
NMPA-Backed Combination Trial Approval | 02/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy